GB201202268D0 - Intracellular immunity - Google Patents

Intracellular immunity

Info

Publication number
GB201202268D0
GB201202268D0 GBGB1202268.7A GB201202268A GB201202268D0 GB 201202268 D0 GB201202268 D0 GB 201202268D0 GB 201202268 A GB201202268 A GB 201202268A GB 201202268 D0 GB201202268 D0 GB 201202268D0
Authority
GB
United Kingdom
Prior art keywords
intracellular immunity
immunity
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1202268.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB1202268.7A priority Critical patent/GB201202268D0/en
Publication of GB201202268D0 publication Critical patent/GB201202268D0/en
Priority to PCT/EP2013/052607 priority patent/WO2013117735A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
GBGB1202268.7A 2012-02-09 2012-02-09 Intracellular immunity Ceased GB201202268D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1202268.7A GB201202268D0 (en) 2012-02-09 2012-02-09 Intracellular immunity
PCT/EP2013/052607 WO2013117735A1 (en) 2012-02-09 2013-02-08 Conjugate comprising an agent and an antiviral ligand and its use in a method for delivering the agent intracellularly

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1202268.7A GB201202268D0 (en) 2012-02-09 2012-02-09 Intracellular immunity

Publications (1)

Publication Number Publication Date
GB201202268D0 true GB201202268D0 (en) 2012-03-28

Family

ID=45929888

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1202268.7A Ceased GB201202268D0 (en) 2012-02-09 2012-02-09 Intracellular immunity

Country Status (2)

Country Link
GB (1) GB201202268D0 (en)
WO (1) WO2013117735A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2517190A (en) * 2013-08-14 2015-02-18 Medical Res Council Intracellular immunity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
JPH04334377A (en) 1990-12-31 1992-11-20 Akzo Nv Acid-instable linker molecule
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
DK1844337T3 (en) 2005-01-24 2013-09-30 Pepscan Systems Bv Binding compounds, immunogenic compounds and peptide mimetics
WO2007084692A2 (en) 2006-01-20 2007-07-26 Welson Pharmaceuticals, Inc. Immunoconjugates for treatment of infectious diseases
JP4145925B2 (en) 2006-01-31 2008-09-03 シャープ株式会社 Plasma etching method
ATE555200T1 (en) 2008-02-05 2012-05-15 Medical Res Council METHODS AND COMPOSITIONS
EP3243527B1 (en) * 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
GB201012410D0 (en) * 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity

Also Published As

Publication number Publication date
WO2013117735A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
HK1248702A1 (en) Substituted pyrrolidine-2-carboxamides
DK3327112T3 (en) Agse-deficient stamme
GB201304182D0 (en) No details
HK1200830A1 (en) Substituted pyrrolidine-2-carboxamides -2-
GB201403961D0 (en) No details
EP2754580A4 (en) Dumptruck
DK2830816T3 (en) Hidtil ukendt coatingkoncept
GB201012410D0 (en) Intracellular immunity
EP2935220A4 (en) Peri-carbinols
HK1206724A1 (en) Substituted benzothienopyrimidines
GB201420527D0 (en) Electrical-wire-protecting member
GB201411220D0 (en) No details
EP2920142A4 (en) Methanofullerenes
EP2934541A4 (en) Substituted noribogaine
HK1206022A1 (en) Substituted imidazopyridazines
GB2518076B (en) Electrical-wire-protecting member
EP2812698A4 (en) Dual-acceptor time-resolved-fret
EP2920157A4 (en) Di-macrocycles
EP2873363A4 (en) Diopsimeter
GB201313844D0 (en) No details
EP2834250A4 (en) Lithiumsilicate
GB201403415D0 (en) No details
GB201202268D0 (en) Intracellular immunity
GB201216568D0 (en) Intracellular immunity
GB201314577D0 (en) Intracellular immunity

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)